Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | PNP | P00491 | 4/20 | 0.65 |
| ▸ | ACP1 | P24666 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | PI4KA | P42356 | 1/20 | 0.57 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.57 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.57 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126819 | 0.87 | ADORA2A (0.60) | MEN1LMNAKMT2APNPADORA2A | |
| SCHEMBL21977361 | 0.86 | LMNA (0.69) | MEN1LMNAKMT2APNPACP1 | |
| SCHEMBL22533355 | 0.82 | MEN1 (0.65) | MEN1LMNAKMT2APNPACP1 | |
| SCHEMBL6675396 | 0.82 | ACP1 (0.70) | MEN1LMNAKMT2APNPACP1 | |
| SCHEMBL18249 | 0.79 | PNP (1.00) | PNP | |
| SCHEMBL1980959 | 0.78 | PNP (0.97) | PNP | |
| SCHEMBL6673665 | 0.78 | ACP1 (0.72) | KMT2APNPACP1ADORA2API4KA | |
| SCHEMBL4559994 | 0.77 | HPRT1 (0.52) | MEN1LMNAKMT2APNPHPRT1 | |
| SCHEMBL20893725 | 0.77 | MAPT (0.60) | MEN1KMT2APNPACP1HPRT1 | |
| SCHEMBL2958439 | 0.77 | SMN1; SMN2 (0.53) | KMT2APNPACP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113480539-B | Synthetic method of nitric acid catalyzed hypoxanthine derivative | 新乡学院 | 2023-03-31 | — | — | CN | disclosed |
| CN-113480539-A | Synthetic method of nitric acid catalyzed hypoxanthine derivative | 新乡学院 | 2021-10-08 | — | — | CN | disclosed |
| US-7781432-B2 | Analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2010-08-24 | — | — | US | disclosed |
| WO-2008131501-A2 | NEW ANTI-VIRAL NUCLEOSIDE ANALOGS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1612210-B1 | New analogs of nitrobenzylthioinosine | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-20070197528-A1 | analgesic. especially acute, chronic and/or neuropathic pain; epilepsy and other CNS-related disorders as well as for neuroprotection or cardioprotection; 9-benzyl-8-(cyclopentylamine)-6-(4-nitrobenzyl-mercaptopurine | GRUENENTHAL GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1761534-A2 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006002846-A2 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1612210-A1 | New analogs of nitrobenzylthioinosine | Grünenthal GmbH (DE) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197528-A1 | analgesic. especially acute, chronic and/or neuropathic pain; epilepsy and other CNS-related disorders as well as for neuroprotection or cardioprotection; 9-benzyl-8-(cyclopentylamine)-6-(4-nitrobenzyl-mercaptopurine | TPMT, NLN, NNMT | MEN1 4207/4885LMNA 2880/4885KMT2A 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.